Key points from article :
Carcinotech, based in Edinburgh, uses 3D printing to create personalized tumors for cancer research and treatment.
Carcino3D bioprinters create micro-tumors from a patient's own cells, mimicking their tumor microenvironment.
This allows for faster, more accurate drug testing and development of personalized cancer treatments.
Carcinotech recently secured £4.2 million to expand its offering in the UK, Europe, and eventually the US.
They collaborate with pharmaceutical companies, surgeons, and other experts to accelerate drug discovery.
In October 2023, Carcinotech’s 3D printed tumor offering was expanded through a partnership with 3D bioprinting firm CELLINK.
Carcinotech is strengthening its team and expanding its reach to bring personalized cancer care to more patients.
